ReviewFrontiers in immunology2025
The research progress of LACC1.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laccase Domain-Containing 1(LACC1)is highly expressed in myeloid macrophages, and plays a crucial role in coordinating innate and adaptive immune responses by integrating lipid, polyamine, and purine metabolism pathways. This study comprehensively discusses the molecular structure, enzymatic functions, and signaling pathways associated with LACC1. Notably, the M-CSF/AKT/mTOR/LACC1 pathway primarily regulates cellular autophagy. Additionally, the PPARα/RXR/PPRE/LACC1, miR-211-5p/KDM2B/LACC1, LACC1/AMPK/NLRP3, LACC1/NF-kB, LACC1/MAPK, LACC1/ROS/NOD2/PIPK2, LACC1/JAK-STAT, and LACC1/CCL5 signaling pathways are significantly involved in modulating inflammatory responses. Furthermore, the article provides a comprehensive summary of the pathogenic mechanisms and recent advancements in research concerning LACC1 in immune diseases, metabolic disorders, infectious diseases, and neurological conditions. In conclusion, LACC1 serves as a pivotal immune-metabolic hub, offering new insights and potential therapeutic targets for the study of related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.